{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:46:32Z","timestamp":1782571592454,"version":"3.54.5"},"reference-count":165,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.yexcr.2021.112968","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T19:39:21Z","timestamp":1638819561000},"page":"112968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies"],"prefix":"10.1016","volume":"410","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3664-4620","authenticated-orcid":false,"given":"Giuseppe","family":"Angelini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-0727","authenticated-orcid":false,"given":"Graziella","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2021.112968_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.yexcr.2021.112968_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.yexcr.2021.112968_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.9.2.493","article-title":"Satellite cell of skeletal muscle fibers","volume":"9","author":"Mauro","year":"1961","journal-title":"J. Biophys. Biochem. Cytol."},{"key":"10.1016\/j.yexcr.2021.112968_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.yexcr.2021.112968_bib5","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1093\/hmg\/ddv420","article-title":"Progress and prospects of gene therapy clinical trials for the muscular dystrophies","volume":"25","author":"Bengtsson","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.yexcr.2021.112968_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.trsl.2013.11.006","article-title":"Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks","volume":"163","author":"Rinaldi","year":"2014","journal-title":"Transl. Res."},{"key":"10.1016\/j.yexcr.2021.112968_bib7","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yexcr.2021.112968_bib8","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti\u2013adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.yexcr.2021.112968_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/hum.2016.141","article-title":"Comparison of serum rAAV serotype-specific antibodies in patients with duchenne muscular dystrophy, becker muscular dystrophy, inclusion body myositis, or GNE myopathy","volume":"28","author":"Zygmunt","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yexcr.2021.112968_bib13","doi-asserted-by":"crossref","first-page":"19023","DOI":"10.1073\/pnas.0906591106","article-title":"Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism","volume":"106","author":"Millay","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.yexcr.2021.112968_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.yexcr.2021.112968_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2021.647010","article-title":"Abnormal calcium handling in duchenne muscular dystrophy: mechanisms and potential therapies","volume":"12","author":"Mareedu","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"DMM Dis. Model. Mech."},{"key":"10.1016\/j.yexcr.2021.112968_bib17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.nmd.2018.07.005","article-title":"GsMTx4-D provides protection to the D2.mdx mouse","volume":"28","author":"Ward","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.yexcr.2021.112968_bib18","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.1038\/s41598-020-70987-y","article-title":"The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy","volume":"10","author":"Hammers","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2021.112968_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10974-017-9470-z","article-title":"Physiology and pathophysiology of excitation\u2013contraction coupling: the functional role of ryanodine receptor","volume":"38","author":"Santulli","year":"2017","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.yexcr.2021.112968_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nm.1916","article-title":"Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle","volume":"15","author":"Bellinger","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/jcm9020520","article-title":"Dysregulation of calcium handling in duchenne muscular dystrophy-associated dilated cardiomyopathy: mechanisms and experimental therapeutic strategies","volume":"9","author":"Law","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1096\/fj.201700182RRR","article-title":"Ryanodine channel complex stabilizer compound S48168\/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy","volume":"32","author":"Capogrosso","year":"2018","journal-title":"Faseb. J."},{"key":"10.1016\/j.yexcr.2021.112968_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddab100","article-title":"Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice","author":"Nogami","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.yexcr.2021.112968_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ymthe.2019.12.011","article-title":"Single SERCA2a therapy ameliorated dilated cardiomyopathy for 18 Months in a mouse model of duchenne muscular dystrophy","volume":"28","author":"Wasala","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nature10980","article-title":"Hsp72 preserves muscle function and slows progression of severe muscular dystrophy","volume":"484","author":"Gehrig","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2021.112968_bib26","doi-asserted-by":"crossref","first-page":"C699","DOI":"10.1152\/ajpcell.00341.2014","article-title":"SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models","volume":"308","author":"M\u00e1zala","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib27","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1139\/cjpp-2017-0265","article-title":"Na+-H+ exchanger and proton channel in heart failure associated with becker and duchenne muscular dystrophies","volume":"95","author":"Bkaily","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.yexcr.2021.112968_bib28","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1128\/MCB.00339-14","article-title":"Na+ dysregulation coupled with Ca2+ entry through NCX1 promotes muscular dystrophy in mice","volume":"34","author":"Burr","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.yexcr.2021.112968_bib29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2353\/ajpath.2007.070452","article-title":"Enhanced Na+\/H+ exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of p2 receptors","volume":"171","author":"Iwata","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yexcr.2021.112968_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104999","article-title":"Rimeporide as a first- in-class NHE-1 inhibitor: results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy","volume":"159","author":"Previtali","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.yexcr.2021.112968_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijcard.2020.03.031","article-title":"Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs","volume":"312","author":"Ghaleh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib32","first-page":"S215","article-title":"Rimeporide: safety, tolerability and pharmacokinetic results from a phase Ib study in DMD boys as well as exploratory biomarkers, Neuromuscul","volume":"27","author":"Gidaro","year":"2017","journal-title":"Disord"},{"key":"10.1016\/j.yexcr.2021.112968_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tcm.2009.04.006","article-title":"Cardiac consequences to skeletal muscle-centric therapeutics for duchenne muscular dystrophy","volume":"19","author":"Townsend","year":"2009","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib34","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/hmg\/ddt112","article-title":"Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy","volume":"22","author":"Wasala","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.yexcr.2021.112968_bib35","series-title":"Muscle and Cardiac Therapeutic Strategies for Duchenne Muscular Dystrophy: Past, Present, and Future","author":"\u0141oboda","year":"2020"},{"key":"10.1016\/j.yexcr.2021.112968_bib36","doi-asserted-by":"crossref","first-page":"9734","DOI":"10.3390\/nu7125498","article-title":"Metabogenic and nutriceutical approaches to address energy dysregulation and skeletal muscle wasting in duchenne muscular dystrophy","volume":"7","author":"Rybalka","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.yexcr.2021.112968_bib37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/cdd.2016.127","article-title":"Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy","volume":"24","author":"Vila","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.yexcr.2021.112968_bib38","doi-asserted-by":"crossref","first-page":"148250","DOI":"10.1016\/j.bbabio.2020.148250","article-title":"Transport of Ca2+ and Ca2+-dependent permeability transition in heart mitochondria in the early stages of Duchenne muscular dystrophy","volume":"1861","author":"Dubinin","year":"2020","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"10.1016\/j.yexcr.2021.112968_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2020.00690","article-title":"Mitochondrial dysfunction is an early consequence of partial or complete dystrophin loss in mdx mice","volume":"11","author":"Moore","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/jcsm.12405","article-title":"Early myopathy in Duchenne muscular dystrophy is associated with elevated mitochondrial H2O2 emission during impaired oxidative phosphorylation","volume":"10","author":"Hughes","year":"2019","journal-title":"J. Cachexia. Sarcopenia Muscle."},{"key":"10.1016\/j.yexcr.2021.112968_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox10040520","article-title":"Metabolic targets of coenzyme q10 in mitochondria","volume":"10","author":"Hidalgo-Guti\u00e9rrez","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.yexcr.2021.112968_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nmd.2019.10.008","article-title":"Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy","volume":"30","author":"Servais","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.yexcr.2021.112968_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2016.05.008","article-title":"Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy","volume":"26","author":"Meier","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.yexcr.2021.112968_bib44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1021\/acsmedchemlett.8b00287","article-title":"Selective PPAR\u03b4 modulators improve mitochondrial function: potential treatment for duchenne muscular dystrophy (DMD)","volume":"9","author":"Lagu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.yexcr.2021.112968_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mito.2018.02.006","article-title":"PPAR\u03b4 modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophy","volume":"46","author":"Bell","year":"2019","journal-title":"Mitochondrion"},{"key":"10.1016\/j.yexcr.2021.112968_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox9121268","article-title":"Nitric oxide (NO) and duchenne muscular dystrophy: NO way to go?","volume":"9","author":"Timpani","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.yexcr.2021.112968_bib47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s13311-016-0494-7","article-title":"Attempting to compensate for reduced neuronal nitric oxide synthase protein with nitrate supplementation cannot overcome metabolic dysfunction but rather has detrimental effects in dystrophin-deficient mdx muscle","volume":"14","author":"Timpani","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yexcr.2021.112968_bib48","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jcp.25075","article-title":"Pathways implicated in tadalafil amelioration of duchenne muscular dystrophy","volume":"231","author":"De Arcangelis","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/path.4054","article-title":"Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy","volume":"228","author":"Percival","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.yexcr.2021.112968_bib50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy","volume":"76","author":"Leung","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.yexcr.2021.112968_bib51","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy","volume":"89","author":"Victor","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.yexcr.2021.112968_bib52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1042\/cs0630519","article-title":"Muscle protein synthesis measured by stable isotope techniques in man: the effects of feeding and fasting","volume":"63","author":"Rennie","year":"1982","journal-title":"Clin. Sci."},{"key":"10.1016\/j.yexcr.2021.112968_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3177\/jnsv.38.141","article-title":"Protein and energy metabolism in patients with progressive muscular dystrophy","volume":"38","author":"Okada","year":"1992","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"10.1016\/j.yexcr.2021.112968_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1022465203458","article-title":"Effects of creatine supplementation on performance and training adaptations","volume":"244","author":"Kreider","year":"2003","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.yexcr.2021.112968_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.52.4.854","article-title":"Creatine monohydrate increases strength in patients with neuromuscular disease","volume":"52","author":"Tarnopolsky","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yexcr.2021.112968_bib56","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mus.10355","article-title":"Beneficial effects of creatine supplementation in dystrophic patients","volume":"27","author":"Louis","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.yexcr.2021.112968_bib57","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1212\/WNL.54.9.1848","article-title":"Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study","volume":"54","author":"Walter","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yexcr.2021.112968_bib58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/B:NERE.0000010442.89826.9c","article-title":"Taurine and skeletal muscle disorders","volume":"29","author":"Camerino","year":"2004","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.yexcr.2021.112968_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.trsl.2018.09.004","article-title":"A long-term treatment with taurine prevents cardiac dysfunction in mdx mice","volume":"204","author":"Mele","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.yexcr.2021.112968_bib60","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.biocel.2013.07.009","article-title":"Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice","volume":"45","author":"Terrill","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.yexcr.2021.112968_bib61","doi-asserted-by":"crossref","first-page":"C483","DOI":"10.1152\/ajpcell.00046.2017","article-title":"Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation","volume":"314","author":"Barker","year":"2018","journal-title":"Am. J. Physiol. Physiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib62","doi-asserted-by":"crossref","first-page":"14659","DOI":"10.1038\/s41598-018-32613-w","article-title":"Supplementation with a selective amino acid formula ameliorates muscular dystrophy in mdx mice","volume":"8","author":"Banfi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2021.112968_bib63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-510X(98)00258-5","article-title":"Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state","volume":"161","author":"Disatnik","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.yexcr.2021.112968_bib64","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1097\/00002060-200211001-00018","article-title":"Oxidative stress and the pathogenesis of muscular dystrophies","volume":"81","author":"Rando","year":"2002","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.yexcr.2021.112968_bib65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-145-5-200609050-00006","article-title":"The effect of polyphenols in olive oil on heart disease risk factors","volume":"145","author":"Covas","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib66","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/carcin\/19.4.611","article-title":"Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols","volume":"19","author":"Yang","year":"1998","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yexcr.2021.112968_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035712","article-title":"Resveratrol mediated modulation of sirt-1\/runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation","volume":"7","author":"Shakibaei","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2021.112968_bib68","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1\u03b1","volume":"127","author":"Lagouge","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2021.112968_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030063","article-title":"Rescue of dystrophic skeletal muscle by PGC-1\u03b1 involves a fast to slow fiber type shift in the mdx mouse","volume":"7","author":"Selsby","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2021.112968_bib70","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1124\/jpet.111.183210","article-title":"Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for duchenne muscular dystrophy","volume":"338","author":"Hori","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.yexcr.2021.112968_bib71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1139\/cjpp-2013-0350","article-title":"Resveratrol improves muscle function but not oxidative capacity in young mdx mice","volume":"92","author":"Gordon","year":"2014","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.yexcr.2021.112968_bib72","doi-asserted-by":"crossref","first-page":"15555","DOI":"10.1038\/s41598-018-33930-w","article-title":"Resveratrol ameliorates mitophagy disturbance and improves cardiac pathophysiology of dystrophin-deficient mdx mice","volume":"8","author":"Kuno","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2021.112968_bib73","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/molecules26040853","article-title":"Resveratrol promotes hypertrophy in wildtype skeletal muscle and reduces muscle necrosis and gene expression of inflammatory markers in mdx mice","volume":"26","author":"Woodman","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.yexcr.2021.112968_bib74","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clnu.2012.06.003","article-title":"Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy","volume":"32","author":"Gordon","year":"2013","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.yexcr.2021.112968_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/181260","article-title":"Molecular mechanisms and therapeutic effects of (-)-epicatechin and other polyphenols in cancer, inflammation, diabetes, and neurodegeneration","author":"Shay","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.yexcr.2021.112968_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/mus.27108","article-title":"(\u2212)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy","volume":"63","author":"McDonald","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.yexcr.2021.112968_bib77","first-page":"189","volume":"11","author":"Khairani","year":"2020","journal-title":"Mol. Mech. Anthocyan. Potent. Nutraceut. Muscle Regener."},{"key":"10.1016\/j.yexcr.2021.112968_bib78","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.foodchem.2005.11.004","article-title":"Phenolic profiles of Andean purple corn (Zea mays L.)","volume":"100","author":"Pedreschi","year":"2007","journal-title":"Food Chem."},{"key":"10.1016\/j.yexcr.2021.112968_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2332-4","article-title":"Nutritional intervention with cyanidin hinders the progression of muscular dystrophy","volume":"11","author":"Saclier","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexcr.2021.112968_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.yexcr.2021.112968_bib81","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/mol.107.038794","article-title":"Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?","volume":"72","author":"Newton","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yexcr.2021.112968_bib82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-200556","article-title":"Mechanisms and clinical applications of glucocorticoid steroids in muscular dystrophy","volume":"8","author":"Quattrocelli","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.yexcr.2021.112968_bib83","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1016\/j.ajpath.2017.07.017","article-title":"Intermittent glucocorticoid dosing improves muscle repair and function in mice with limb-girdle muscular dystrophy","volume":"187","author":"Quattrocelli","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yexcr.2021.112968_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-01758-9","article-title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better?","volume":"16","author":"Kourakis","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexcr.2021.112968_bib85","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.yexcr.2021.112968_bib86","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/CIRCULATIONAHA.111.031716","article-title":"Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice","volume":"124","author":"Rafael-Fortney","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.yexcr.2021.112968_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.119.013501","article-title":"Stabilization of early duchenne cardiomyopathy with aldosterone inhibition: results of the multicenter AIDMD trial","volume":"8","author":"Raman","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.yexcr.2021.112968_bib88","doi-asserted-by":"crossref","DOI":"10.1096\/fj.02-0542com","article-title":"Mechanical stress activates the nuclear factor\u2010kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy","author":"Kumar","year":"2003","journal-title":"Faseb. J."},{"key":"10.1016\/j.yexcr.2021.112968_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2021.02.001","article-title":"Disease-modifying effects of edasalonexent, an NF-\u03baB inhibitor, in young boys with Duchenne muscular dystrophy: results of the MoveDMD phase 2 and open label extension trial: running title: Edasalonexent for Duchenne muscular dystrophy","author":"Finkel","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.yexcr.2021.112968_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.842","article-title":"A novel NF-\u03baB inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects","author":"Donovan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.yexcr.2021.112968_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2015.12.003","article-title":"Preclinical characterization and clinical development of ILARIS\u00ae (canakinumab) for the treatment of autoinflammatory diseases","volume":"32","author":"Gram","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.yexcr.2021.112968_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13395-015-0066-2","article-title":"CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy","volume":"5","author":"Pinto-Mariz","year":"2015","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.yexcr.2021.112968_bib93","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.nmd.2014.06.102","article-title":"Novel inhibitor of hematopoietic prostaglandin D synthase improves the muscle disorder in an experimental model of Duchenne muscular dystrophy","volume":"24","author":"Tanaka","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.yexcr.2021.112968_bib94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/acn3.50978","article-title":"Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.yexcr.2021.112968_bib95","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/acn3.651","article-title":"A phase I study of TAS-205 in patients with Duchenne muscular dystrophy","volume":"5","author":"Takeshita","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.yexcr.2021.112968_bib96","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0022-510X(83)90207-1","article-title":"A quantitative study of the muscle satellite cells in various neuromuscular disorders","volume":"62","author":"Ishimoto","year":"1983","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.yexcr.2021.112968_bib97","doi-asserted-by":"crossref","first-page":"R961","DOI":"10.1152\/ajpregu.00146.2004","article-title":"Regenerative capacity of the dystrophic (mdx) diaphragm after induced injury","volume":"287","author":"Matecki","year":"2004","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib98","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00441-010-0976-6","article-title":"Elevated satellite cell number in Duchenne muscular dystrophy","volume":"340","author":"Kottlors","year":"2010","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.yexcr.2021.112968_bib99","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03390","article-title":"Post-transcriptional regulation of satellite cell quiescence by TTP-mediated mRNA decay","volume":"4","author":"Hausburg","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.yexcr.2021.112968_bib100","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1073\/pnas.80.15.4856","article-title":"Defective myoblasts identified in Duchenne muscular dystrophy","volume":"80","author":"Blau","year":"1983","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.yexcr.2021.112968_bib101","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF01233096","article-title":"Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy","volume":"16","author":"Webster","year":"1990","journal-title":"Somat. Cell Mol. Genet."},{"key":"10.1016\/j.yexcr.2021.112968_bib102","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0960-8966(99)00093-0","article-title":"Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children","volume":"10","author":"Decary","year":"2000","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.yexcr.2021.112968_bib103","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mus.20824","article-title":"Telomere shortening in diaphragm and tibialis anterior muscles of agedmdx mice","volume":"36","author":"Lund","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.yexcr.2021.112968_bib104","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/hmg\/ddu194","article-title":"Rapid depletion of muscle progenitor cells in dystrophic mdx\/utrophin\u2212\/\u2212 mice","volume":"23","author":"Lu","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.yexcr.2021.112968_bib105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.molmed.2016.04.002","article-title":"Satellite cells in muscular dystrophy - lost in polarity","volume":"22","author":"Chang","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib106","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib107","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/(SICI)1097-4644(20000101)76:1<118::AID-JCB12>3.0.CO;2-F","article-title":"Defective growth in vitro of Duchenne muscular dystrophy myoblasts: the molecular and biochemical basis","volume":"76","author":"Melone","year":"2000","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.yexcr.2021.112968_bib108","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm1536","article-title":"Angiotensin II type 1 receptor blockade attenuates TGF-\u03b2\u2013induced failure of muscle regeneration in multiple myopathic states","volume":"13","author":"Cohn","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib109","doi-asserted-by":"crossref","first-page":"151","DOI":"10.11005\/jbm.2020.27.3.151","article-title":"Myostatin inhibitors: panacea or predicament for musculoskeletal disorders?","volume":"27","author":"Suh","year":"2020","journal-title":"J. Bone Metab."},{"key":"10.1016\/j.yexcr.2021.112968_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122657","article-title":"The failed clinical story of myostatin inhibitors against duchenne muscular dystrophy: exploring the biology behind the battle","volume":"9","author":"Rybalka","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2021.112968_bib111","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/WCO.0000000000000853","article-title":"The elusive promise of myostatin inhibition for muscular dystrophy","volume":"33","author":"Wagner","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.yexcr.2021.112968_bib112","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm1479","article-title":"Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors","volume":"12","author":"Minetti","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib113","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/epi.14.36","article-title":"Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy","volume":"6","author":"Consalvi","year":"2014","journal-title":"Epigenomics"},{"key":"10.1016\/j.yexcr.2021.112968_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.yexcr.2021.112968_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01098-y","article-title":"Silencing Nfix rescues muscular dystrophy by delaying muscle regeneration","volume":"8","author":"Rossi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexcr.2021.112968_bib116","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1083\/jcb.142.6.1461","article-title":"Progressive muscular dystrophy in \u03b1-sarcoglycan-deficient mice","volume":"142","author":"Duclos","year":"1998","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.yexcr.2021.112968_bib117","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cell.2010.01.027","article-title":"Nfix regulates fetal-specific transcription in developing skeletal muscle","volume":"140","author":"Messina","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2021.112968_bib118","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.celrep.2016.02.014","article-title":"Nfix regulates temporal progression of muscle regeneration through modulation of myostatin expression","volume":"14","author":"Rossi","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.yexcr.2021.112968_bib119","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00673.2004","article-title":"Deficiency of \u03b1-sarcoglycan differently affects fast- and slow-twitch skeletal muscles","author":"Danieli-Betto","year":"2005","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.yexcr.2021.112968_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/0092-8674(88)90463-1","article-title":"Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy","author":"Webster","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2021.112968_bib121","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/cells9030708","article-title":"The transcription factor Nfix requires RhoA-ROCK1 dependent phagocytosis to mediate macrophage skewing during skeletal muscle regeneration","volume":"9","author":"Saclier","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2021.112968_bib122","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3869","article-title":"Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro\/adipogenic progenitors","author":"Lemos","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib123","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.matbio.2018.01.014","article-title":"Regulation of fibrosis in muscular dystrophy","volume":"68\u201369","author":"Smith","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.yexcr.2021.112968_bib124","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.matbio.2018.03.007","article-title":"Connective tissue growth factor (CTGF) from basics to clinics","volume":"68\u201369","author":"Ramazani","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.yexcr.2021.112968_bib125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3892\/etm.2017.4105","article-title":"Expression levels of TGF-\u03b21 and CTGF are associated with the severity of duchenne muscular dystrophy","volume":"13","author":"Song","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib126","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2007.09.043","article-title":"Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy","volume":"267","author":"Sun","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.yexcr.2021.112968_bib127","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1093\/hmg\/ddt352","article-title":"Reducing CTGF\/CCN2 slows down mdx muscle dystrophy and improves cell therapy","volume":"22","author":"Morales","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.yexcr.2021.112968_bib128","article-title":"In vitro assessment of anti-fibrotic activity does not predict their in vivo efficacy in murine models of Duchenne muscular dystrophy","author":"Theret","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.yexcr.2021.112968_bib129","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1089\/hum.2018.151","article-title":"Gene and cell therapy for muscular dystrophies: are we getting there?","volume":"29","author":"Galli","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","author":"Verhaart","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.yexcr.2021.112968_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.yexcr.2021.112968_bib132","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in duchenne's muscular dystrophy","author":"Goemans","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib133","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"issue":"80-","key":"10.1016\/j.yexcr.2021.112968_bib135","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.yexcr.2021.112968_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward gene therapy for duchenne muscular dystrophy","author":"Chamberlain","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib137","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexcr.2021.112968_bib138","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1389200219666180305154119","article-title":"Pharmacokinetics, metabolism, distribution and permeability of nanomedicine","volume":"19","author":"Ravindran","year":"2018","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.yexcr.2021.112968_bib139","doi-asserted-by":"crossref","first-page":"14357","DOI":"10.1002\/anie.201908357","article-title":"Bioinspired core\u2013shell nanoparticles for hydrophobic drug delivery","volume":"58","author":"Yang","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.yexcr.2021.112968_bib140","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.3390\/molecules25122866","article-title":"Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy","volume":"25","author":"Wahane","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.yexcr.2021.112968_bib141","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.yexcr.2021.112968_bib142","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12951-019-0489-8","article-title":"Environmental hazard assessment for polymeric and inorganic nanobiomaterials used in drug delivery","volume":"17","author":"Hauser","year":"2019","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.yexcr.2021.112968_bib143","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zieli\u0144ska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.yexcr.2021.112968_bib144","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2147\/IJN.S125521","article-title":"The complex of PAMAM-OH dendrimer with Angiotensin (1-7) prevented the disuse-induced skeletal muscle atrophy in mice","volume":"12","author":"M\u00e1rquez-Miranda","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.yexcr.2021.112968_bib145","doi-asserted-by":"crossref","first-page":"1805730","DOI":"10.1002\/adma.201805730","article-title":"Degradability and clearance of inorganic nanoparticles for biomedical applications","volume":"31","author":"Yang","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.yexcr.2021.112968_bib146","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00775-018-1542-z","article-title":"Pilar Chantada, Inorganic nanoparticles in diagnosis and treatment of breast cancer","volume":"23","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"10.1016\/j.yexcr.2021.112968_bib147","doi-asserted-by":"crossref","first-page":"113642","DOI":"10.1016\/j.jpba.2020.113642","article-title":"Analytical characterization of liposomes and other lipid nanoparticles for drug delivery","volume":"192","author":"Fan","year":"2021","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.yexcr.2021.112968_bib148","doi-asserted-by":"crossref","first-page":"110768","DOI":"10.1016\/j.msec.2020.110768","article-title":"Microfluidic-assisted polymer-protein assembly to fabricate homogeneous functionalnanoparticles","volume":"111","author":"Zhang","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.yexcr.2021.112968_bib149","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.yexcr.2021.112968_bib150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/pharmaceutics10030151","article-title":"Development of dual drug loaded nanosized liposomal formulation by A reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies","volume":"10","author":"Sarfraz","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yexcr.2021.112968_bib151","doi-asserted-by":"crossref","first-page":"18806","DOI":"10.1039\/C9NR05788A","article-title":"The role of apolipoprotein- and vitronectin-enriched protein corona on lipid nanoparticles for in vivo targeted delivery and transfection of oligonucleotides in murine tumor models","volume":"11","author":"Chen","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.yexcr.2021.112968_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib153","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2017.04.037","article-title":"Long-term regulation of gene expression in muscle cells by systemically delivered siRNA","volume":"256","author":"Baltusnikas","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.yexcr.2021.112968_bib154","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41551-019-0436-x","article-title":"Engineering patient-specific cancer immunotherapies","volume":"3","author":"Scheetz","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.yexcr.2021.112968_bib155","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.yexcr.2021.112968_bib156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13020278","article-title":"Nanomedicine for gene delivery and drug repurposing in the treatment of muscular dystrophies","volume":"13","author":"Andreana","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yexcr.2021.112968_bib157","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1089\/hum.2015.107","article-title":"Perspective on adeno-associated virus capsid modification for duchenne muscular dystrophy gene therapy","volume":"26","author":"Nance","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib158","article-title":"Clinical relevance of pre-existing and treatment-induced anti-poly(ethylene glycol) antibodies","author":"Freire Haddad","year":"2021","journal-title":"Regen. Eng. Transl. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib159","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae - the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.yexcr.2021.112968_bib160","doi-asserted-by":"crossref","first-page":"1900061","DOI":"10.1002\/adtp.201900061","article-title":"Polyrotaxane nanocarriers can deliver CRISPR\/Cas9 plasmid to dystrophic muscle cells to successfully edit the DMD gene","author":"Emami","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.yexcr.2021.112968_bib161","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.biomaterials.2018.11.027","article-title":"Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo","volume":"192","author":"Ji","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.yexcr.2021.112968_bib162","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.yexcr.2021.112968_bib163","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1096\/fj.13-237388","article-title":"Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function","volume":"28","author":"Bibee","year":"2014","journal-title":"Faseb. J."},{"key":"10.1016\/j.yexcr.2021.112968_bib164","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nano.2018.11.012","article-title":"Liposomal steroid nano-drug is superior to steroids as-is in mdx mouse model of Duchenne muscular dystrophy","volume":"16","author":"Turjeman","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.yexcr.2021.112968_bib165","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-021-00911-y","article-title":"Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine","author":"Milane","year":"2021","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721005243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721005243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:20:17Z","timestamp":1762147217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482721005243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":165,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0014482721005243"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112968","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112968"}}